PARIS--(BUSINESS WIRE)--Regulatory News:
Cellectis S.A. (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced its results for the three- and six-month periods ended June 30, 2015.
Help employers find you! Check out all the jobs and post your resume.
